A detailed history of Cva Family Office, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cva Family Office, LLC holds 348 shares of VRTX stock, worth $163,949. This represents 0.03% of its overall portfolio holdings.

Number of Shares
348
Previous 339 2.65%
Holding current value
$163,949
Previous $158,000 1.9%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$460.0 - $505.78 $4,140 - $4,552
9 Added 2.65%
348 $161,000
Q2 2024

Jul 09, 2024

BUY
$392.81 - $485.53 $5,106 - $6,311
13 Added 3.99%
339 $158,000
Q1 2024

Apr 10, 2024

BUY
$407.69 - $446.08 $407 - $446
1 Added 0.31%
326 $136,000
Q4 2023

Jan 16, 2024

BUY
$343.0 - $410.68 $111,475 - $133,471
325 New
325 $132,000
Q2 2023

Jul 10, 2023

BUY
$314.42 - $351.91 $1,572 - $1,759
5 Added 1.69%
300 $105,000
Q1 2023

Apr 26, 2023

SELL
$283.23 - $323.1 $28,323 - $32,310
-100 Reduced 25.32%
295 $92,000
Q4 2022

Feb 21, 2023

BUY
$285.76 - $321.48 $34,291 - $38,577
120 Added 43.64%
395 $114,000
Q3 2022

Nov 22, 2022

BUY
$273.83 - $305.53 $10,953 - $12,221
40 Added 17.02%
275 $80,000
Q1 2022

Apr 22, 2022

BUY
$221.42 - $260.97 $29,891 - $35,230
135 Added 135.0%
235 $61,000
Q4 2021

Jan 25, 2022

BUY
$177.01 - $223.45 $17,701 - $22,345
100 New
100 $22,000
Q3 2021

Oct 12, 2021

SELL
$181.39 - $202.99 $16,506 - $18,472
-91 Closed
0 $0
Q2 2021

Jul 13, 2021

SELL
$187.49 - $221.1 $11,999 - $14,150
-64 Reduced 41.29%
91 $18,000
Q1 2021

Apr 14, 2021

BUY
$207.02 - $241.31 $32,088 - $37,403
155 New
155 $33,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cva Family Office, LLC Portfolio

Follow Cva Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cva Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cva Family Office, LLC with notifications on news.